ClinicalTrials.gg
WithdrawnNCT03697824Updated Oct 29, 2019

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

A Phase 2 interventional study of GSK3377794 and Pembrolizumab in Neoplasms, sponsored by GlaxoSmithKline. Withdrawn. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.

Primary conditionSarcoma, SynovialRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sarcoma, Synovial
Why
  1. The study's title name Sarcoma, Synovial, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Internal decision, study will be replaced with a larger monotherapy trial

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
10 Years and older
Sex
All
01

Study summary

Adoptive T-cell therapy is a therapeutic approach that aims to generate an anti-tumor T-cell immune response by infusing a cancer subjects own T-cells obtained by leukapheresis, engineered and expanded in-vitro to express a tumor specific T-cell receptor. NY-ESO-1 and LAGE-1a antigens are tumor-associated proteins that have been found in several tumor types, including synovial sarcoma. This is an open-label study to evaluate the safety and efficacy of GSK3377794 (genetically engineered NY-ESO-1 Specific [c259] T Cells), in combination with anticancer agents including pembrolizumab in subjects with NY-ESO-1 and/or LAGE-1a positive relapsed and refractory synovial sarcoma. The study will consist of a target expression screening to determine if subjects are human leukocyte antigen (HLA)-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive and if their tumors express NY-ESO-1 and/or LAGE-1a, followed by a leukapheresis screening phase of up to 42 days prior to leukapheresis. Eligible subjects will enter a leukapheresis phase followed by lymphodepletion phase with cyclophosphamide and fludarabine. During the treatment phase, subjects will be administered GSK3377794 on Day 1 followed by pembrolizumab infusion once every 3 weeks from Day 22 (or Week 7) for up to 2 years. There will be a long-term follow-up phase from the end of treatment phase and for up to 15 years from the date of GSK3377794 administration.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • HLA-A2+
  • Synovial Sarcoma
  • pembrolizumab
  • NY-ESO-1
  • GSK3377794
  • LAGE-1a
03

In context

Sarcoma, Synovial Reclassified

133 studies on the registry are indexed under Sarcoma, Synovial; 29 are open to participants now.

Browse Sarcoma, Synovial studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Sarcoma, Synovial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Target Expression Screening Phase: Subject must be >=10 years of age at the time of signing the . Younger subjects may only be enrolled upon consultation with Sponsor.
  • or histologically confirmed advanced synovial sarcoma that is either or unresectable and is either currently being treated with or has completed at least one line of standard chemotherapy regimen or subject is intolerant to it. Subjects can also undergo leukapheresis prior to initiating or standard therapy.
  • Radiologically detectable disease.
  • >=3 months.
  • In the investigator's opinion, the subject is suitable for leukapheresis and, subsequently, for GSK3377794 and pembrolizumab infusion.
  • An archival or fresh biopsy (if collected as part of standard of care) of tumor tissue is required to perform antigen expression analysis.
  • Male or female subjects will be included. requirements will apply at the time of leukapharesis and treatment.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol. For subjects \<18 years of age (or the legal minimum age in the relevant country) their legal guardian must give informed consent. Pediatric subjects will be included in age-appropriate discussion in order to obtain verbal assent.
  • Leukapheresis Phase: In addition to the criteria mentioned above, the following criteria must also apply.
  • Subject's tumor has been reviewed by the GlaxoSmithKline (GSK)-designated laboratory and confirmed as meeting the pre-defined threshold for expression of NY-ESO-1 and/or, if tested, LAGE-1a, using archival or fresh (if taken as standard of care) biopsy.
  • HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 by high resolution testing.
  • >=40%, or Fractional Shortening >=28%.
  • Performance status: of 0-1 or for subjects \<=10 years of age, Lansky >60.
  • Subject must have adequate organ function 7 days prior to leukapheresis.
  • Male or female subjects will be included. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. a) Male subjects are eligible to participate if they agree to the following during the intervention period starting at the first dose of chemotherapy for at least 12 months after receiving the T-cell infusion, or 4 months after there is no evidence of persistence/ gene modified cells in the subject's blood, whichever is longer. Must use effective contraception for at least 4 months after the last dose of pembrolizumab if this time frame is longer than the duration of contraception required in the context of chemotherapy and gene modified cells.
  • Refrain from donating sperm and either: Be abstinent from heterosexual or homosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use contraception/barrier: a) Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception when having sexual intercourse with a woman of (WOCBP) who is not currently pregnant (as a condom may break or leak). b) Agree to use male condom when engaging in any activity that allows for passage of ejaculate to another person.
  • A female subject is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: a) Is not a WOCBP. OR, b) Is a WOCBP who will agree to use a barrier method (male condom) and use a contraceptive method that is highly effective (with a failure rate of \<1% per year), during the intervention period and for at least 12 months after receiving the T-cell infusion, or 4 months after there is no evidence of persistence/ gene modified cells in the subjects blood, whichever is longer. WOCBP must use effective contraception for at least 4 months after the last dose of pembrolizumab if this time frame is longer than the duration of contraception required in the context of chemotherapy and gene modified cells. WOCBP should also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. c) A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before any dose of study intervention. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the subject must be excluded from participation if the serum pregnancy result is positive. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Lymphodepletion and Treatment Phase: In addition to the criteria mentioned above, the following criteria must also apply:
  • Subject has been treated with at least one line of standard chemotherapy regimen and is intolerant of or not actively responding to this regimen (i.e. the subject should not be taken prematurely off their primary regimen if they are continuing to respond to it).
  • Subject must be presenting with at least two lesions: one measurable per 1.1 and the other required for biopsy. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Central nervous system (CNS) metastases with low CNS disease burden are allowed on a case by case basis after risk-benefit evaluation in consultation with the Sponsor Medical Monitor (or designee) if: a) Asymptomatic; b) Clinically stable; c) No history of bleeding within ; d) No lesions in the brain stem; e) No untreated ; f) No spinal cord compression; g) Not requiring escalating anti-epileptic treatment; h) Not requiring treatment with ; i) If treated with focal radiotherapy (for example, gamma knife radiosurgery), there is at least a 2-week ; j) Not treated with whole brain radiotherapy within the prior 4 weeks.
  • Lymphodepleting regimen initiation is allowed if: a) There is clinical and/or radiographic evidence of disease progression; b) If supportive therapy (chemotherapy or radiotherapy) was used, the wash-out periods have been fulfilled; c) Supportive radiotherapy has not affected >25% of bone marrow; d) Following intermediate standard of care line of therapy.
  • Another line of standard of care therapy may be administered between leukapheresis and treatment if: a) Indicated based on risk/benefit assessment and/or local regulatory requirements and following agreement with Sponsor's Medical Monitor (or designee); b) Treatments, adverse events and other clinical observations are reported in this study database
  • A biopsy (excisional, incisional, or core) of tumor tissue obtained following cessation of the last line of treatment for synovial sarcoma but prior to initiating lymphodepleting chemotherapy is mandatory (if it is not feasible to obtain a fresh biopsy, archival tumor tissue is required).

Exclusion criteria

Exclusion Criteria:

  • Target Expression Screening Phase: Prior other than synovial sarcoma: a) Subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. b) Subjects with previous malignancies that have been definitively treated, and have been in remission may be enrolled upon consultation with sponsor Medical Monitor or designee.
  • Previous treatment with genetically engineered NY-ESO-1 specific T cells.
  • Previous NY-ESO-1 vaccine.
  • Prior gene therapy using an integrating vector.
  • Previous hematopoietic stem cell transplant.
  • systemic illness (e.g. serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the judgment of the Investigator would compromise the subject's ability to tolerate protocol therapy or significantly increase the risk of complications.
  • Leukapheresis Phase: In addition, to the above criteria subjects are not eligible for leukapharesis if any of the following criteria apply:
  • Has chronic, recurrent, or active /immune-mediated disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  • Uncontrolled intercurrent illness including, but not limited to: a) Ongoing or active infection requiring systemic therapy; b) Clinically significant cardiac disease defined by congestive heart failure (NYHA) Class >1; c) Uncontrolled clinically significant arrhythmia in last 6 months; d) Acute coronary syndrome (angina or myocardial infarction) in last 6 months; e) Severe aortic stenosis or symptomatic mitral stenosis; f) Inadequate pulmonary function with mechanical parameters \<40% predicted ( [FEV1], Forced vital capacity [FVC], Total lung capacity [TLC], Diffusing capacity of the lung for carbon monoxide [DLCO]); g) Interstitial lung disease (subjects with existing pneumonitis as a result of radiation are not excluded; however, subjects cannot be oxygen dependent); h) Any other illness that in the judgment of the Investigator would compromise the subjects ability to tolerate protocol therapy or significantly increase the risk of complications
  • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver or otherwise stable chronic liver disease per investigator assessment).
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
  • interval duration (QTc) >450 milliseconds (msec) or QTc >480 msec for subjects with bundle branch block. The QTc is the QT interval corrected for heart rate according to Bazett's formula (QTcB), Fridericia's formula (QTcF), and/or another method, machine-read or manually over-read.
  • Subject has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, other agents used in the study (Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule).
  • Has severe (>=Grade 3) to pembrolizumab and/or any of its .
  • Pregnant or breastfeeding females (due to risk to fetus or newborn).
  • Any prior treatment-related toxicities must be (Version 4.03) \<=Grade 1 at the time of initiating study intervention (except for non-clinically significant toxicities e.g., alopecia, vitiligo). Subjects with Grade 2 toxicities that are deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled on a case-by-case basis in agreement between the Investigator and Sponsor's Medical Monitor (or designee).
  • Other standard of care are allowed only if guidelines and are followed.
  • treatment within 30 days or 5 half-lives (whichever is shorter) prior to leukapheresis. Investigational vaccines (other than NY-ESO-1 vaccines that are not allowed) must follow the wash-out period. Exceptions to this rule must be evaluated by the Investigator in agreement with the Sponsor's Medical Monitor (or designee).
  • Presence of surface antigen (HBsAg), positive antibody test result at screening or within 3 months prior to first dose of study intervention. Subjects with positive Hepatitis C antibody due to prior resolved disease are can be enrolled, only if a confirmatory negative Hepatitis C ribonucleic acid (RNA) polymerase chain reaction (PCR) test is obtained.
  • A positive test for antibody.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study.
  • Lymphodepletion and Treatment Phase: In addition to the criteria mentioned above, subjects are not eligible for lymphodepletion or treatment if any of the following criteria apply: Subject has received cytotoxic therapy within 2 weeks prior to lymphodepleting chemotherapy: a. Subjects must have recovered from all AEs due to previous therapies to \<=Grade 1 or Baseline. Subjects with \<=Grade 2 neuropathy are eligible. b. Systemic corticosteroids or any other immunosuppressive therapy within 2 weeks prior to lymphodepleting chemotherapy.
  • within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed.
  • Major surgery \<=28 days of first dose of study intervention.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    GSK3377794+pembrolizumab

    After screening, eligible subjects will enter a leukapheresis phase, followed by lymphodepletion phase where they will be administered fludarabine and cyclophosphamide. On Day 1, subjects will receive a single dose of GSK3377794 administered as an intravenous infusion of 1 to 6 x10\^9 total transduced cells. On Day 22, subjects will be administered pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks for adults and 2 mg/kilogram (kg) (up to 200 mg) once every 3 weeks for children for up to 35 cycles (2 years) or until subsequent disease progression.

    Drug: GSK3377794 · Drug: Pembrolizumab · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.

  • Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.

  • Fludarabine will be used as a lymphodepleting chemotherapy.

  • Cyclophosphamide will be used as a lymphodepleting chemotherapy.

06

What researchers measure

Primary outcomes

  1. Number of subjects with treatment limiting toxicities (TLT)

    The following toxicities will be considered as TLTs: Any \>=Grade 4 adverse event (AE) except for Grade 4 fever and chills and Grade 4 hypoalbuminemia or abnormal electrolytes that are responding to supplementation/correction; Grade 3 non-infectious pneumonitis; Any other Grade 3 AE (excluding pneumonitis), that does not improve to Grade 2 within 7 days after onset despite medical management and supportive care; Any AE that permanently prevents subject from dosing with pembrolizumab in this trial.

    Time frame: Up to 2 years

  2. Number of subjects with AEs

    An AE is any untoward medical occurrence in a clinical study subject, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 2 years

  3. Severity of AEs

    The severity of AEs will be graded according to National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) version 4.03.

    Time frame: Up to 2 years

Secondary outcomes

  1. Number of subjects with serious adverse events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events that may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed before.

    Time frame: Up to 2 years

  2. Number of subjects with AE /SAEs leading to pembrolizumab administration delay, interruptions, and withdrawals

    Number of subjects with AE /SAEs leading to pembrolizumab administration delay, interruptions, and withdrawals will be summarized.

    Time frame: Up to 2 years

  3. Number of subjects with abnormal hematology parameters

    Blood samples will be collected for the assessment of the following hematology parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils.

    Time frame: Up to 2 years

  4. Number of subjects with abnormal clinical chemistry parameters

    Blood samples will be collected for the assessment of the following clinical chemistry parameters: blood urea nitrogen (BUN), creatinine, glucose, albumin, potassium, sodium, calcium, phosphorus, magnesium, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, lactate dehydrogenase (LDH), bicarbonate, total and direct bilirubin, total protein, chloride and urea.

    Time frame: Up to 2 years

  5. Number of subjects with abnormal urine parameters

    Urine samples will be collected for the analysis of the following urine parameters: specific gravity, potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite and leukocyte esterase by dipstick.

    Time frame: Up to 2 years

  6. Number of subjects with abnormal vital signs

    Vital signs will be measured in a semi-supine position after 5 minutes of rest and will include temperature, systolic and diastolic blood pressure, and pulse rate.

    Time frame: Up to 2 years

  7. Eastern Cooperative Oncology Group (ECOG) performance scores

    For subjects \>10 years of age, the performance status will be assessed using ECOG.

    Time frame: Up to 2 years

  8. Lansky performance scores

    For subjects \<=10 years of age, the performance status will be assessed using Lansky scale.

    Time frame: Up to 2 years

  9. Number of subjects with abnormal electrocardiogram (ECG) parameters

    12-lead ECG will be obtained in triplicate using an automated ECG machine.

    Time frame: Up to 2 years

  10. Overall Response Rate

    Overall response rate is defined as the percentage of subjects with a confirmed complete response (CR) or a partial response (PR) at any time as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to 2 years

  11. Progression free survival

    Progression-free survival is defined as the time from the date of T-cell infusion until the earliest date of disease progression (PD) as assessed by the investigator per RECIST version 1.1, or death due to any cause.

    Time frame: Up to 2 years

  12. Disease Control Rate

    Disease Control Rate is defined as the percentage of subjects with a confirmed CR, PR, or stable disease (SD) for at least 6 months as per RECIST version 1.1.

    Time frame: Up to 2 years

  13. Duration of Response

    Duration of response is defined as the time from first documented evidence of CR or PR until the first documented sign of disease progression or death, in the subset of subjects who show a confirmed CR or PR.

    Time frame: Up to 2 years

  14. Time to Response

    Time to response is defined as the time from the first dose to the first documented evidence of CR or PR for subjects with a confirmed CR or PR.

    Time frame: Up to 2 years

  15. Maximum transgene persistence (Cmax)

    Peripheral blood samples will be collected at indicated time points for measurement of GSK3377794 transduced cell quantities. GSK3377794 T-cell persistence in the peripheral blood will be measured to establish the relationship between persistence and response to GSK3377794.

    Time frame: Day -14 to Day -9, Days 1, 2, 4, 8, 15, 22, Weeks 5, 7 and once every 3 weeks from Week 10 to 106

  16. Time to Cmax (Tmax)

    Peripheral blood samples will be collected at indicated time points for measurement of GSK3377794 transduced cell quantities. GSK3377794 T-cell persistence in the peripheral blood will be measured to establish the relationship between persistence and response to GSK3377794.

    Time frame: Day -14 to Day -9, Days 1, 2, 4, 8, 15, 22, Weeks 5, 7 and once every 3 weeks from Week 10 to 106

  17. Area under the time curve from zero to time t (AUC[0-t])

    Peripheral blood samples will be collected at indicated time points for measurement of GSK3377794 transduced cell quantities. GSK3377794 T-cell persistence in the peripheral blood will be measured to establish the relationship between persistence and response to GSK3377794.

    Time frame: Day -14 to Day -9, Days 1, 2, 4, 8, 15, 22, Weeks 5, 7 and once every 3 weeks from Week 10 to 106

  18. Number of subjects with NY-ESO-1/LAGE-1a expression in tumor tissues

    Biopsy of tumor tissue will be obtained to assess the tissue expression of the target antigen NY-ESO-1 and/or LAGE-1a.

    Time frame: Up to 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2019; primary completion for Jul 2022, 40 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2018
First posted
Oct 5, 2018
StartEst.
Feb 25, 2019
Primary completionEst.
Jul 18, 2022
CompletionEst.
Jul 18, 2022
Last update
Oct 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03697824
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 5, 2018
Start date
Feb 25, 2019 (estimated)
Primary completion
Jul 18, 2022 (estimated)
Completion
Jul 18, 2022 (estimated)
Last update
Oct 29, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letetresgene autoleucel

Start the discussion